An observational study in Refractory Epilepsy and Development Delay, sponsored by Zogenix, Inc.. Terminated at 19 sites in 4 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.
Sponsored by Zogenix, Inc. (part of UCB S.A.) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Drug Resistant Epilepsy with a site in Germany — 2 open to participants now, 4 under way, 1 of them phase 3. Drug Resistant Epilepsy · Germany.
Among the 11 studies in Drug Resistant Epilepsy with a site in Germany, this one is one of 3 that started in 2019, is one of 3 observational ones, and was the 6th registered.
258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.
Browse Drug Resistant Epilepsy studies →2 of the 11 studies in Drug Resistant Epilepsy with a site in Germany are open now. Recruiting first, the newest first:
Biohaven Therapeutics Ltd. · Sites in Germany, United States, Argentina and 24 more countries
Ages 18–75
Duke University · Sites in Germany, United States, Australia and 9 more countries
Ages 15+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 3
First in 2012; this study’s year is marked. 3 started in 2019.
This study's enrollment of 93 is close to the median of 86 across 45 observational studies indexed under Drug Resistant Epilepsy.
Median enrollment 320 across the 8 interventional studies, 191 across the 3 observational. Of the 7 that completed or were terminated, 3 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix, Inc. is the lead sponsor of 19 studies on the registry; none are open to participants now.
UCB S.A. has 4 studies filed under Drug Resistant Epilepsy — fewer than ten, so there is no comparison to draw.
2 of the studies in Drug Resistant Epilepsy with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT06138808Duke University5-SENSE Score Validation Study | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Drug Resistant Epilepsy with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review).
This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review). The identified local site staff (or trained independent data abstractors, if requested by the site) will review the medical records of all participants meeting the eligibility criteria, who have provided a signed inform consent form (ICF) for data collection and analysis. For participants who are less than 18 years of age, in addition to the assent form being signed by the participant, an informed consent would be obtained from parental or legally authorized representative.
In line with the retrospective nature of the study: there is no assignment of a participant to a particular therapeutic strategy; no additional diagnostic or monitoring procedures shall be applied to the participants; epidemiological methods shall be used for the analysis of collected data; the prescription of any medication for the treatment of the epileptic syndrome occur before the collection of the data in this study and is clearly separated from the decision to include the participant in the study.
Participants with rare epilepsy syndromes up to the date of the most recent visit at the study site.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of Participants With and Without Diagnosis of an Epilepsy Syndrome
Understand the proportion of participants with and without diagnosis of an epilepsy syndrome, as described by the International League Against Epilepsy (ILAE) diagnostic manual located at https://www.epilepsydiagnosis.org/
Time frame: 5 months
Understand the Clinical Practice Criteria
Understand the clinical practice criteria used for specific syndromic diagnosis of participants with refractory epilepsy associated with developmental delay.
Time frame: 5 months
Clinical Practice Diagnostic Criteria Compared to ILAE
Compare clinical practice diagnostic criteria to those proposed by the ILAE and identify potential areas of educational need.
Time frame: 5 months
Understand the Time to Formal Diagnosis
Understand the time to diagnosis, from first seizure to formal diagnosis of a specific syndrome.
Time frame: 5 months
Unclassified Epilepsy
Evaluate if unclassified epilepsy can be grouped with common electroclinical phenotype features.
Time frame: 5 months
Ran from Mar 2019 to primary completion in Sep 2020, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.